<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Romel Somwar(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer
|Clinical Cancer Research|2020|381
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
|Journal of Thoracic Oncology|2019|97
HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
|Clinical Cancer Research|2024|16